In a patient with prior coronary stent and myocardial infarction who develops shortness of breath and pruritus with clopidogrel and ticagrelor (Brilinta), what alternative antiplatelet medication should be given?

Prasugrel is the recommended alternative antiplatelet agent

For a patient with prior MI and coronary stent who develops shortness of breath and pruritus with both clopidogrel and ticagrelor (Brilinta), prasugrel should be the next P2Y12 inhibitor, provided the patient has no history of stroke or TIA. 1, 2, 3, 4, 5

Clinical Reasoning

Why These Reactions Occurred

The shortness of breath is a well-documented side effect of ticagrelor, occurring in 14-21% of patients and leading to discontinuation in up to 6.9% 6. The pruritus with clopidogrel represents a hypersensitivity reaction. These are distinct mechanisms—ticagrelor causes dyspnea through adenosine-mediated effects, while clopidogrel reactions are immunologic 7, 8.

The Prasugrel Solution

Prasugrel is structurally different enough from clopidogrel that cross-reactivity is unlikely 7. Guidelines explicitly recommend prasugrel as an alternative when patients cannot tolerate aspirin or other P2Y12 inhibitors 1, 2, 3, 4, 5.

Dosing:

• Loading dose: 60 mg
• Maintenance: 10 mg daily
• Continue for at least 12 months post-stent 3, 4, 9, 5

Critical Contraindications to Check

Prasugrel is absolutely contraindicated if:

• Prior stroke or TIA (Class III: Harm) 3, 4, 9, 10
• Active pathological bleeding 4
• Age ≥75 years (generally not recommended unless high-risk features like diabetes or prior MI) 1, 4
• Weight <60 kg (consider 5 mg maintenance dose) 1, 4

If Prasugrel is Contraindicated

Alternative strategies in order of preference:

1. Clopidogrel desensitization protocol - Can overcome hypersensitivity in select cases 7

2. Cilostazol + aspirin - Phosphodiesterase-3 inhibitor with antiplatelet effects, shown effective in aspirin-intolerant patients and may work for clopidogrel-intolerant patients 11, 12, 13. Dosing: 100 mg twice daily

3. GP IIb/IIIa inhibitors (short-term bridge only) - Eptifibatide or tirofiban during acute phase, then transition to oral therapy 1, 3, 4

4. Aspirin alone - If all P2Y12 inhibitors fail, though this significantly increases thrombotic risk in the first 12 months post-stent 2, 9

Common Pitfalls to Avoid

• Do not rechallenge with ticagrelor - The dyspnea will recur and may worsen 6, 8
• Do not assume cross-reactivity between all P2Y12 inhibitors - Prasugrel has a different structure and metabolism than clopidogrel 7
• Do not use prasugrel if any stroke/TIA history - This increases intracranial hemorrhage risk unacceptably 3, 4, 9
• Do not stop antiplatelet therapy abruptly - This dramatically increases stent thrombosis risk; bridge with alternative agent 9

Monitoring After Prasugrel Initiation

• Watch for bleeding complications (more common than with clopidogrel) 4, 10
• Ensure aspirin dose is 75-100 mg daily (not higher) 9, 5, 9
• Continue for minimum 12 months, then reassess based on bleeding vs. ischemic risk 9